MIMEDX GROUP, INC. (NASDAQ:MDXG) Files An 8-K Results of Operations and Financial Condition
Item 2.02
|
Results of Operations and Financial Condition
|
press release announcing its financial results for the first
quarter of 2017 and certain other matters. The release also
announced that executives of the Company would discuss these
results with investors on a conference call broadcast via the
Companys website located at www.mimedx.com>and provided access
information, date and time for the conference call. A copy of the
press release is furnished herewith as Exhibit 99.1 to this
Current Report on Form 8-K and is incorporated herein by
reference.
considered furnished and shall not be deemed to be filed for
purposes of Section 18 of the Securities Exchange Act of 1934, as
amended, nor shall it be deemed incorporated by reference in any
filing under the Securities Act of 1933, as amended, except as
shall be expressly set forth by specific reference in such
filing.
|
Item 9.01
|
Financial Statements and Exhibits
|
|
(c)
|
Exhibits
|
|
Exhibit No.
|
Description
|
|
|
99.1
|
MiMedx Group, Inc. Press Release, dated April 28, 2017
|
About MIMEDX GROUP, INC. (NASDAQ:MDXG)
MiMedx Group, Inc. (MiMedx) is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues and human skin and bone. The Company operates in the Regenerative Biomaterials business segment, which includes the development, processing and marketing of regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues in the wound care, surgical, sports medicine, ophthalmic and dental market categories. Its biomaterial platform technologies are AmnioFix, EpiFix, OrthoFlo, Physio, AlloBurn, and CollaFix. AmnioFix and EpiFix are its tissue technologies processed from human amniotic membrane derived from donated placentas. The Company processes the human amniotic membrane utilizing its PURION Process, to produce an implant. MiMedx is the supplier of amniotic tissue, having supplied over 500,000 allografts. MIMEDX GROUP, INC. (NASDAQ:MDXG) Recent Trading Information
MIMEDX GROUP, INC. (NASDAQ:MDXG) closed its last trading session 00.00 at 11.40 with 1,406,514 shares trading hands.
